NVO vs. NVS
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Novartis AG (NVS).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or NVS.
Correlation
The correlation between NVO and NVS is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
NVO vs. NVS - Performance Comparison
Loading data...
Key characteristics
NVO:
-1.13
NVS:
0.60
NVO:
-1.72
NVS:
0.87
NVO:
0.78
NVS:
1.12
NVO:
-0.83
NVS:
0.56
NVO:
-1.50
NVS:
1.19
NVO:
32.77%
NVS:
9.31%
NVO:
42.92%
NVS:
20.02%
NVO:
-71.29%
NVS:
-41.72%
NVO:
-53.47%
NVS:
-5.12%
Fundamentals
NVO:
$284.34B
NVS:
$216.45B
NVO:
$3.52
NVS:
$6.38
NVO:
18.29
NVS:
17.18
NVO:
0.97
NVS:
1.30
NVO:
0.94
NVS:
4.07
NVO:
13.78
NVS:
5.64
NVO:
$303.14B
NVS:
$52.86B
NVO:
$255.65B
NVS:
$39.86B
NVO:
$154.08B
NVS:
$21.88B
Returns By Period
In the year-to-date period, NVO achieves a -20.83% return, which is significantly lower than NVS's 17.87% return. Over the past 10 years, NVO has outperformed NVS with an annualized return of 11.03%, while NVS has yielded a comparatively lower 6.56% annualized return.
NVO
-20.83%
15.39%
-31.77%
-48.17%
9.18%
17.53%
11.03%
NVS
17.87%
-0.14%
11.31%
11.82%
13.76%
10.77%
6.56%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. NVS — Risk-Adjusted Performance Rank
NVO
NVS
NVO vs. NVS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
NVO vs. NVS - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 2.41%, less than NVS's 3.61% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 2.41% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
NVS Novartis AG | 3.61% | 3.84% | 3.44% | 3.91% | 4.08% | 3.40% | 2.87% | 3.72% | 3.50% | 4.06% | 3.51% | 3.14% |
Drawdowns
NVO vs. NVS - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.29%, which is greater than NVS's maximum drawdown of -41.72%. Use the drawdown chart below to compare losses from any high point for NVO and NVS. For additional features, visit the drawdowns tool.
Loading data...
Volatility
NVO vs. NVS - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 12.68% compared to Novartis AG (NVS) at 6.92%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
NVO vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. NVS - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 65.20B and revenue of 78.09B. Therefore, the gross margin over that period was 83.5%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novartis AG reported a gross profit of 10.39B and revenue of 13.62B. Therefore, the gross margin over that period was 76.3%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 38.79B and revenue of 78.09B, resulting in an operating margin of 49.7%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novartis AG reported an operating income of 4.66B and revenue of 13.62B, resulting in an operating margin of 34.2%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 29.03B and revenue of 78.09B, resulting in a net margin of 37.2%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novartis AG reported a net income of 3.61B and revenue of 13.62B, resulting in a net margin of 26.5%.